Nigeria Pharmaceutical Unit-dose Packaging Market Size & Outlook, 2026-2034
Nigeria Pharmaceutical Unit-dose Packaging Market Insights
- As highlighted in Packaging Market Insights analysis, the Nigeria Pharmaceutical Unit-dose Packaging Market, worth USD 291.49 Million in 2025, is forecasted to achieve USD 1060.46 Million by 2034.
- The Nigeria market is anticipated to grow at a CAGR of 15.48% during the period 2026–2034.
- By 2025, Plastics represented the largest share of the By Material market size.
- Paper and Paperboard is expected to remain the key growth driver within By Material, registering the fastest CAGR during the forecast period.
Source: PIAnalysis Company Publications, Primary Interviews.
Other Key Findings
- In 2025, Nigeria accounted for 0.62% of the global Pharmaceutical Unit-dose Packaging Market size.
- By 2034, United States is expected to lead the global Pharmaceutical Unit-dose Packaging Market in terms of market size.
- Within Middle East and Africa, United Arab Emirates is projected to dominate the regional Pharmaceutical Unit-dose Packaging Market size by 2034.
- Nigeria is identified as the fastest-growing market in Middle East and Africa, anticipated to reach USD 1064.6 Million by 2034.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2025 |
| Study Period | 2021-2034 |
| Historical Period | 2021-2024 |
| Forecast Period | 2026-2034 |
| Market Size In 2025 | USD 291.49 Million |
| Market Size In 2034 | USD 1060.46 Million |
| Largest segment | Plastics |
| Units | Revenue in USD Million |
| CAGR | 15.48% (2026-2034) |
| Segmnetation Covered | |
| By Material |
|
| By Product |
|
| By End-use |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Nigeria Pharmaceutical Unit-dose Packaging Market By Material 2026-2034 (USD Million)
| By Material | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Plastics | XX.x | XX.x | XX.x | 101.46 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Glass | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Paper and Paperboard | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Metal | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
Nigeria Pharmaceutical Unit-dose Packaging Market By Product 2026-2034 (USD Million)
| By Product | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vials | XX.x | XX.x | XX.x | 106.75 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Syringe and cartridge | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Ampoules | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Blisters | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.
Nigeria Pharmaceutical Unit-dose Packaging Market By End-use 2026-2034 (USD Million)
| By End-use | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ophthalmic | XX.x | XX.x | XX.x | 85.33 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Injectable | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Biologics | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Wound Care | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Respiratory Therapy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Orals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: PIAnalysis Company Publications, Primary Interviews.